This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 10/30/2023 11:12 AM

HOLD Punjab National Bank

Better margins, lower opex/LLP drive strong earnings beat

BFSI - Banks > Result Update > October 27, 2023

PNB reported a beat on PAT, at Rs17.6bn (vs Emkay: Rs14.6bn), mainly owing to higher NII, lower staff expense and contained provisions, and partially offset by the higher tax expense. Bank's credit growth trajectory improved to 15% YoY/3% QoQ which, coupled with better loan/investment, led to a 3bps QoQ improvement in NIM to 3.1%, while most banks saw a correction. Asset quality continues to enhance, with GNPA ratio down by 77bps QoQ to 7%, aided by lower slippages and higher recoveries/upgrades. Going ahead, PNB expects growth to remain robust, albeit NIMs to slightly soften amid rising CoF. However, better treasury gains, recovery from written-off accounts and contained LLP should support profitability. We expect the bank to note a gradual improvement in RoA/RoE to 0.7%/11% by FY26E, from a low of 0.2% in FY23. We retain HOLD on PNB, with new TP of Rs78/sh (earlier Rs65), rolling forward on Sep-25E ABV and subs value at Rs5/sh. Management clarified the bank is not looking to divest stake in subsidiaries, incl. its insurance business, for now.

Punjab National Ban	k: Financial	Snapshot	(Standalon	e)	
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Net profit	34,570	25,072	66,337	97,372	1,23,014
Loan growth (%)	8.0	14.1	13.3	13.5	14.2
NII growth (%)	(6.1)	20.2	14.0	8.4	9.8
NIM (%)	2.5	2.7	2.8	2.7	2.7
PPOP growth (%)	(6.3)	8.5	7.1	0.0	10.0
Adj. EPS (Rs)	3.2	2.3	6.0	8.8	11.2
Adj. EPS growth (%)	37.0	(29.2)	164.6	46.8	26.3
Adj. BV (INR)	56.3	67.7	79.2	86.1	94.3
Adj. BVPS growth (%)	8.2	20.1	17.1	8.7	9.5
RoA (%)	0.3	0.2	0.4	0.6	0.7
RoE (%)	4.0	2.8	7.1	9.7	11.2
P/E (x)	20.2	28.6	10.8	7.4	5.8
P/ABV (x)	1.2	1.0	0.8	0.8	0.7

Source: Company, Emkay Research

Growth improves, as do margins

Credit growth improved to 15% YoY/3% QoQ, backed by continued growth in the RAM segment (which constitutes 56% of the total loan book), while Corporate growth was muted at 1% QoQ. Total deposits grew 10% YoY/1% QoQ, with CASA remaining stable at 41%. Despite the increase in CoF to 4.3% (due to repricing of deposits), NIMs saw a slight improvement of 3bps QoQ to 3.1%, owing to better yield on loans/investments. The bank conservatively guides for 12-13% credit growth in FY24 with upward bias and NIM of 2.9-3%, as it envisages further increase in CoF due to repricing of deposits.

Lower slippages lead to sharp improvement in asset quality

Lower fresh slippages at Rs18.3bn/0.9% of loans, coupled with higher recovery/ upgrades, led to a 77bps QoQ decline in the GNPA ratio to 7%. Specific PCR further improved to 80%; the bank plans to maintain this high level and thus bring down the NNPA from its current 1.5% levels. The restructured pool also declined, by 7bps QoQ to 1.1% of loans, and stands at Rs101bn. The bank recovered NPAs to the tune of ~Rs11bn from NCLT in H1FY24, and expects more recoveries, of Rs25bn in H2FY24. The bank guides for credit cost of 1.5-1.75% for FY24 vs 2.1% in FY23.

We retain HOLD on the stock

We expect the bank to report gradual improvement in its RoA/RoE to 0.7%/11% by FY26E, from a low of 0.2% in FY23. We retain HOLD on the stock, with revised target price of Rs78/share (earlier Rs65/share), rolling forward on Sep-25E ABV and subsidiaries' value at Rs5/share. Management has clarified that the bank is not looking to divest stake in its subsidiaries, including its insurance business, for now. **Key risks:** Macro deterioration derailing growth/asset-quality normalization.



Ticker

TARGET PRICE (Rs): 78

Target Price – 12M	Sep-24
Change in TP (%)	20.0
Current Reco.	HOLD
Previous Reco.	HOLD
Upside/(Downside) (%)	11.7
CMP (26-Oct-23) (Rs)	69.9

Stock Data

otoen butu	menter
52-week High (Rs)	84
52-week Low (Rs)	39
Shares outstanding (mn)	11,011.0
Market-cap (Rs bn)	769
Market-cap (USD mn)	9,241
Net-debt, FY24E (Rs mn)	NA
ADTV-3M (mn shares)	73
ADTV-3M (Rs mn)	5,152.7
ADTV-3M (USD mn)	61.9
Free float (%)	27.0
Nifty-50	18,857
INR/USD	83.2
Shareholding, Sep-23	
Promoters (%)	73.2
FPIs/MFs (%)	2.7/13.8

Price Performance								
(%)	1M	3M	12M					
Absolute	(12.0)	10.6	61.3					
Rel. to Nifty	(8.2)	16.0	51.0					

1-Year share price trend (Rs)



Anand Dama

anand.dama@emkayglobal.com +91 22 6624 2480

Kunaal N

kunaal.n@emkayglobal.com +91 22 6612 1275


Marazbaan Dastur

marazbaan.dastur@emkayglobal.com +91 22 6612 1281

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 10/30/2023 11:12 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAYsGO>Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.


Story in Charts

Exhibit 1: Credit growth improves, but deposit growth remains moderate




Source: Company, Emkay Research

Exhibit 3: Domestic CASA was unwavering at 42%



Source: Company, Emkay Research

Exhibit 5: Lower slippages along with better recovery/upgrade led to improvement in asset quality




Source: Company, Emkay Research


1.2

1.0


0.8

Exhibit 7: PNB is reasonably valued vs peers





Source: Bloomberg, Emkay Research




Source: Company, Emkay Research

Exhibit 4: Slippages were contained at 0.9% of loans




Source: Company, Emkay Research

Exhibit 6: We expect the bank to report gradual improvement in return ratios, going forward



Source: Company, Emkay Research

Exhibit 8: The stock currently trades at 0.8x its 1-year forward ABV



Source: Company, Bloomberg, Emkay Research

(Resear rt is intended

This report is intended for team emkay @ whitemarcuresolutions com use and downloaded at 10/30/2023 11:12 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore. research report or research

Exhibit 9: Actuals vs Estimates (Q2FY24)

(Rs mn)	Actuals	Estimates		Variation		Variation		Variation		Variation		Comments
		Emkay	Consensus	Emkay Consensus								
Net income	1,29,512	1,26,258	1,24,459	3%	4%	Higher NII led to a beat on Net income						
РРОР	62,164	55,966	62,017	11%	0%	Higher net income and lower staff expenses led to a beat						
PAT	17,561	14,626	16,195	20%	8%	Higher PPOP and contained provisions led to a beat						

Source: Company, Emkay Research

Exhibit 10: Quarterly Summary

(Rs mn)	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	YoY (%)	QoQ (%)	FY23	FY24E	YoY (%)
Interest Earned	2,01,540	2,23,844	2,38,486	2,51,455	2,63,549	31	5	8,51,441	10,73,486	26
Interest Exp	1,18,833	1,32,051	1,43,499	1,56,412	1,64,320	38	5	5,06,525	6,80,124	34
Net Interest Income	82,707	91,794	94,988	95,043	99,229	20	4	3,44,916	3,93,362	14
Global NIMs (reported)	3.00	3.16	3.24	3.08	3.11	11bps	3bps	2.70	2.75	6bps
Non-interest Income	28,472	33,380	34,203	34,338	30,283	6	-12	1,21,425	1,31,489	8
Operating Expenses	55,507	68,014	70,527	69,701	67,348	21	-3	2,41,054	2,83,519	18
Pre Provisioning Profit	55,672	57,159	58,664	59,680	62,164	12	4	2,25,288	2,41,332	7
Provision & Contingencies	49,064	47,133	38,306	39,653	34,442	-30	-13	1,82,405	1,39,275	-24
PBT	6,608	10,026	20,359	20,027	27,723	320	38	42,883	1,02,057	138
Income Tax Expense (Gain)	2,496	3,737	8,772	7,473	10,161	307	36	17,811	35,720	101
Net Profit/(Loss)	4,113	6,289	11,586	12,554	17,561	327	40	25,072	66,337	165
Gross NPA (%)	10.47	9.75	8.73	7.73	6.96	-351bps	-77bps	8.73	6.40	-233bps
Net NPA (%)	3.79	3.29	2.72	1.98	1.47	-232bps	-51bps	2.72	1.35	-137bps
Deposits (Rs bn)	11,935	12,104	12,812	12,979	13,099	10	1	12,812	13,972	9
Net Advances (Rs bn)	7,734	8,004	8,308	8,637	8,899	15	3	8,308	9,411	13

Source: Company, Emkay Research

Exhibit 11: Revision in Estimates

Y/E Mar (Rs mn)	FY24E			FY25E			FY26E		
	Earlier	Revised	Change	Earlier	Revised	Change	Earlier	Revised	Change
Net income	5,07,476	5,24,852	3.4%	5,42,765	5,51,388	1.6%	5,97,207	6,01,937	0.8%
РРОР	2,20,259	2,41,332	9.6%	2,25,355	2,41,307	7.1%	2,48,440	2,65,406	6.8%
PAT	60,743	66,337	9.2%	98,044	97,372	-0.7%	1,19,481	1,23,014	3.0%
EPS (Rs)	5.5	6.0	9.2%	8.9	8.8	-0.7%	10.9	11.2	3.0%
BV (Rs)	87.4	87.8	0.5%	94.6	94.9	0.3%	103.6	103.8	0.3%

Source: Emkay Research

Exhibit 12: Key Assumption	s			
	FY23A	FY24E	FY25E	FY26E
Loan Growth (%)	14.1	13.3	13.5	14.2
Deposit Growth (%)	11.8	9.1	10.9	11.6
NIM (%)	2.7	2.8	2.7	2.7
GNPA (%)	8.7	6.4	5.0	4.0

1.5

2.1

Source: Emkay Research

Credit Cost (%)

This report is intended for team emkay @whitemarguesolutions com use and downloaded at 10/30/2023 11:12 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

1.0

0.9

Exhibit 13: Key Ratios and Trends

	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24
Loans (Rs bn)	7,366	7,562	7,857	8,011	8,311	8,576	8,856	9,175	9,424
growth (YoY)	2.7	4.0	6.3	10.3	12.8	13.4	12.7	14.5	13.4
growth (QoQ)	1.5	2.7	3.9	2.0	3.7	3.2	3.3	3.6	2.7
Liability Profile									
Deposits (Rs bn)	11,154	11,273	11,462	11,367	11,935	12,104	12,812	12,979	13,099
growth (YoY)	4.3	4.2	3.6	3.6	7.0	7.4	11.8	14.2	9.8
growth (QoQ)	1.6	1.1	1.7	(0.8)	5.0	1.4	5.8	1.3	0.9
Asset Quality and Capital									
GNPA (%)	13.6	12.9	11.8	11.3	10.5	9.7	8.7	7.7	7.0
NNPA (%)	5.0	4.5	4.4	4.0	3.5	3.1	2.6	1.9	1.4
PCR (%)	63.2	65.2	62.2	64.8	66.3	68.5	70.8	75.8	80.0
Slippages (Rs mn)	90,770	44,070	1,05,060	64,680	59,790	40,720	39,960	23,900	18,260
Slippages (%)	5.1	2.4	5.7	3.6	3.2	2.2	2.0	1.2	0.9
CAR (%)	15.2	14.9	14.5	14.8	14.7	15.2	15.5	15.5	15.1
Tier I (%)	12.5	12.2	11.7	12.1	12.2	12.2	12.7	12.3	12.0
ROE Decomposition (on total assets; %)									
NII	2.0	2.4	2.2	2.3	2.5	2.6	2.7	2.6	2.7
Other Income (Ex Treasury)	0.7	0.6	0.6	0.6	0.8	0.9	0.9	0.8	0.8
Treasury	0.3	0.2	0.1	0.2	0.0	0.0	0.1	0.1	0.0
Opex	1.8	1.7	1.4	1.4	1.6	2.0	2.0	1.9	1.8
PPOP	1.3	1.6	1.6	1.6	1.7	1.6	1.6	1.6	1.7
Provisioning Cost	1.0	1.0	1.5	1.5	1.5	1.4	1.1	1.1	0.9
РВТ	0.2	0.5	0.1	0.2	0.2	0.3	0.6	0.5	0.7
Тах	-0.1	0.2	0.1	0.1	0.1	0.1	0.2	0.2	0.3
ROA	0.4	0.4	0.1	0.1	0.1	0.2	0.3	0.3	0.5
ROE	4.7	4.7	0.8	1.3	1.7	2.5	4.7	5.0	6.9

Source: Company, Emkay Research

This report is intended for team emkay@whitemarquesolutions.com use and downloaded at 10/30/2023 11:12 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Punjab National Bank: Standalone Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Interest Income	7,48,795	8,51,441	10,73,486	11,57,408	12,41,302
Interest Expense	4,61,851	5,06,525	6,80,124	7,30,863	7,73,134
Net interest income	2,86,945	3,44,916	3,93,362	4,26,545	4,68,168
NII growth (%)	(6.1)	20.2	14.0	8.4	9.8
Other income	1,23,200	1,21,425	1,31,489	1,24,843	1,33,769
Total Income	4,10,144	4,66,342	5,24,852	5,51,388	6,01,937
Operating expenses	2,02,526	2,41,054	2,83,519	3,10,081	3,36,531
РРОР	2,07,618	2,25,288	2,41,332	2,41,307	2,65,406
PPOP growth (%)	(6.3)	8.5	7.1	0.0	10.0
Core PPOP	1,78,267	2,36,659	2,22,492	2,17,756	2,37,144
Provisions & contingencies	1,64,454	1,82,405	1,39,275	95,976	1,01,387
РВТ	43,164	42,883	1,02,057	1,45,331	1,64,019
Extraordinary items	0	0	0	0	0
Tax expense	8,594	17,811	35,720	47,959	41,005
Minority interest	0	0	0	0	0
Income from JV/Associates	0	0	0	0	0
Reported PAT	34,570	25,072	66,337	97,372	1,23,014
PAT growth (%)	71.0	(27.5)	164.6	46.8	26.3
Adjusted PAT	34,570	25,072	66,337	97,372	1,23,014
Diluted EPS (Rs)	3.2	2.2	5.9	8.7	11.0
Diluted EPS growth (%)	51.9	(29.2)	164.6	46.8	26.3
DPS (Rs)	0.7	0.7	1.2	1.8	2.2
Dividend payout (%)	20.4	28.5	19.9	20.4	19.7
Effective tax rate (%)	19.9	41.5	35.0	33.0	25.0
Net interest margins (%)	2.5	2.7	2.8	2.7	2.7
Cost-income ratio (%)	49.4	51.7	54.0	56.2	55.9
Shares outstanding (mn)	11,011.0	11,011.0	11,011.0	11,011.0	11,011.0

Balance Sheet					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Share capital	22,022	22,022	22,022	22,022	22,022
Reserves & surplus	9,32,847	9,76,535	10,29,271	11,06,475	12,04,865
Net worth	9,54,869	9,98,557	10,51,293	11,28,497	12,26,887
Deposits	114,62,184	128,11,631	139,72,414	154,97,256	172,99,795
Borrowings	4,56,814	5,12,917	5,45,300	5,79,921	6,17,004
Interest bearing liab.	119.18.999	133.24.548	145,17,714	160.77.177	179.16.799
Other liabilities & prov.	2,74,183	2,95,209	3,57,516	3,91,245	4,42,109
Total liabilities & equity	131,48,050	146,18,314	159,26,523	175,96,919	195,85,796
Net advances	72,81,857	83,08,340	94,10,527	106,77,954	121,90,721
Investments	37,21,678	39,59,967	43,21,185	45,91,182	49,09,675
Cash, other balances	13,26,468	15,51,088	13,76,594	14,36,560	15,03,344
Interest earning assets	123,30,002	138,19,395	151,08,306	167,05,696	186,03,740
Fixed assets	1,06,736	1,20,511	1,29,208	1,42,129	1,56,342
Other assets	7,11,312	6,78,408	6,89,009	7,49,094	8,25,714
Total assets	131,48,050	146,18,314	159,26,523	175,96,919	195,85,796
BVPS (Rs)					
DVF3 (KS)	80.3	83.0	87.8	94.9	103.8
Adj. BVPS (INR)	56.3	83.0 67.7	87.8 79.2	86.1	103.8 94.3
			79.2	86.1	94.3
Adj. BVPS (INR)	56.3	67.7	79.2	86.1	94.3
Adj. BVPS (INR) Gross advances	56.3 78,53,575	67.7 88,55,766	79.2 99,18,457	86.1 111,08,672	94.3 125,52,800
Adj. BVPS (INR) Gross advances Credit to deposit (%)	56.3 78,53,575 63.5	67.7 88,55,766 64.8	79.2 99,18,457 67.4	86.1 111,08,672 68.9	94.3 125,52,800 70.5
Adj. BVPS (INR) Gross advances Credit to deposit (%) CASA ratio (%)	56.3 78,53,575 63.5 46.6	67.7 88,55,766 64.8 42.0	79.2 99,18,457 67.4 40.4	86.1 111,08,672 68.9 39.8	94.3 125,52,800 70.5 39.6
Adj. BVPS (INR) Gross advances Credit to deposit (%) CASA ratio (%) Cost of deposits (%)	56.3 78,53,575 63.5 46.6 3.8	67.7 88,55,766 64.8 42.0 3.9	79.2 99,18,457 67.4 40.4 4.8	86.1 111,08,672 68.9 39.8 4.7	94.3 125,52,800 70.5 39.6 4.5
Adj. BVPS (INR) Gross advances Credit to deposit (%) CASA ratio (%) Cost of deposits (%) Loans-to-Assets (%)	56.3 78,53,575 63.5 46.6 3.8 55.4	67.7 88,55,766 64.8 42.0 3.9 56.8	79.2 99,18,457 67.4 40.4 4.8 59.1	86.1 111,08,672 68.9 39.8 4.7 60.7	94.3 125,52,800 70.5 39.6 4.5 62.2

Source: Company, Emkay Research

Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Asset quality					
Gross NPLs	9,24,479.7	7,73,276.0	6,34,913.5	5,59,374.5	5,02,886.9
Net NPLs	3,52,761.6	2,25,850.2	1,26,982.7	1,28,656.1	1,40,808.3
GNPA ratio (%)	11.8	8.7	6.4	5.0	4.0
NNPA ratio (%)	4.8	2.7	1.3	1.2	1.2
Provision coverage (%)	61.8	70.8	80.0	77.0	72.0
Gross slippages	2,47,436.7	1,60,289.2	1,53,736.1	1,88,847.4	2,25,950.4
Gross slippage ratio (%)	3.2	1.8	1.6	1.7	1.8
LLP ratio (%)	2.1	2.1	1.5	1.0	0.9
NNPA to networth (%)	37.7	23.1	12.2	11.5	11.
Capital adequacy					
Total CAR (%)	14.5	15.5	14.7	14.4	14.2
Tier-1 (%)	11.7	12.7	12.4	12.2	12.3
CET-1 (%)	10.6	11.4	11.2	11.1	11.3
RWA-to-Total Assets (%)	45.7	45.1	45.1	45.1	45.3
Miscellaneous					
Total income growth (%)	(6.0)	11.6	23.9	6.4	7.2
Opex growth (%)	(0.3)	19.0	17.6	9.4	8.
Core PPOP growth (%)	(4.3)	32.8	(6.0)	(2.1)	8.9
PPOP margin (%)	1.6	1.6	1.6	18.8	19.3
PAT/PPOP (%)	16.7	11.1	27.5	40.4	46.3
LLP-to-Core PPOP (%)	92.3	77.1	62.6	44.1	42.8
Yield on advances (%)	7.3	7.6	8.7	8.4	8.3
Cost of funds (%)	3.9	4.0	4.9	4.8	4.

Source: Company, Emkay Research

Source: Company, Emkay Research

Valuations and key Ratios						
Y/E Mar	FY22	FY23	FY24E	FY25E	FY26E	
P/E (x)	20.2	28.6	10.8	7.4	5.8	
P/B (x)	1.2	1.0	0.9	0.8	0.7	
P/ABV (x)	1.2	1.0	0.8	0.8	0.7	
P/PPOP (x)	3.7	3.4	3.2	3.2	2.9	
Dividend yield (%)	0.9	0.9	1.7	2.6	3.1	
DuPont-RoE split (%)						
NII/avg assets	2.2	2.5	2.6	2.5	2.5	
Other income	1.0	0.9	0.9	0.7	0.7	
Fee income	0.3	0.3	0.3	0.3	0.3	
Opex	1.6	1.7	1.9	1.8	1.8	
PPOP	1.6	1.6	1.6	1.4	1.4	
Core PPOP	1.4	1.7	1.5	1.3	1.3	
Provisions	1.3	1.3	0.9	0.6	0.5	
Tax expense	0.1	0.1	0.2	0.3	0.2	
RoA (%)	0.3	0.2	0.4	0.6	0.7	
Leverage ratio (x)	15.0	15.4	16.2	16.7	17.0	
RoE (%)	4.0	2.8	7.1	9.7	11.2	
Quarterly data						
Rs mn, Y/E Mar	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	
NII	82,707	91,794	94,988	95,043	99,229	
NIM (%)	3.0	3.2	3.2	3.1	3.1	
PPOP	55,672	57,159	58,664	59,680	62,164	
PAT	4,113	6,289	11,586	12,554	17,561	
EPS (Rs)	0.37	0.57	1.05	1.14	1.59	

Source: Company, Emkay Research

This report is intended for team emkay@whitemarquesolutions com use and downloaded at 10/30/2023 11:12 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RECOMMENDATION HISTORY - DETAILS

Date	CMP (INR)	TP (INR)	Rating	Analyst
07-Oct-23	77	65	Hold	Anand Dama
09-Mar-23	51	48	Hold	Anand Dama
16-Feb-23	51	48	Hold	Anand Dama
18-Nov-22	46	30	Sell	Anand Dama
30-May-22	32	28	Sell	Anand Dama
30-Oct-21	42	35	Sell	Anand Dama
04-Aug-21	39	33	Sell	Anand Dama
08-Jun-21	41	33	Sell	Anand Dama
09-Feb-21	39	29	Sell	Anand Dama
20-Jan-21	37	29	Sell	Anand Dama

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 10/30/2023 11:12 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Emkay Pating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	Over 15%
HOLD	Between -5% to 15%
SELL	Below -5%

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028, India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

DISCLAIMERS AND DISCLOSURES: Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house.EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited(NSE), MCX Stock Exchange Limited (MCX-SX).EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her relative's financial interest in the subject company. (NO)

EGFSL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report.

Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: (NO)

EGFSL or its associates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of EGFSL or its associates during twelve months preceding the date of distribution of the research report and EGFSL may have co-managed public offering of securities for the subject company in the past twelve months.

The research Analyst has served as officer, director or employee of the subject company: (NO)

The Research Analyst has received any compensation from the subject company in the past twelve months: (NO)

The Research Analyst has managed or co-managed public offering of securities for the subject company in the past twelve months: (NO)

The Research Analyst has received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months: (NO)

The Research Analyst has received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months: (NO)

The Research Analyst has received any compensation or other benefits from the subject company or third party in connection with the research report; (NO)

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.